Clinical development failure
Pipeline value depends on proving safety and efficacy in human trials.
- Scope
- Lead programs in CHD, CHB, and oncology
- Materiality
- high
Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. Its pipeline includes antibody-based, masked T-cell engager, and siRNA programs, with development and manufacturing activities centered in San Francisco and supported by third-party collaborators and CDMOs.
−682,1 %
100,0 %
−638,9 %
−7,6 %
5.54
5.54
| % | |
|---|---|
| Infectious disease therapeutics | 40% Programs aimed at chronic hepatitis delta, hepatitis B, HIV cure, and other serious infectious diseases. |
| Oncology immunotherapies | 30% Dual-masked T-cell engager programs targeting validated solid tumor antigens. |
| Preclinical pipeline | 15% Earlier-stage discovery programs across infectious disease and oncology targets. |
| Collaboration and license revenue | 15% Revenue from partnered programs, licenses, grants, and research services. |
Vir does not sell a broad commercial product portfolio today; its economic counterparties are primarily...
- Biopharmaceutical collaboration partnersprimary
Partners such as GSK, Norgine, Alnylam, and Astellas that license programs, share development costs, or commercialize assets.
- Government and private grant sponsorssecondary
Organizations funding research programs, especially in infectious disease and HIV cure work.
- Healthcare providers and treatment centerssecondary
Hospitals, specialists, and oncology/infectious disease clinicians that would prescribe approved therapies.
- Patients with serious infectious disease or cancerprimary
End users of the company’s future approved medicines, especially CHD, CHB, and solid tumor patients.
Vir is headquartered in the United States, with process development and small-scale manufacturing activities at its San...
- •Headquartered in San Francisco, California
- •Core development and small-scale cGMP work is done in the U.S.
- •Commercial rights may be split by territory with partners
- •Ex-U.S. commercialization can be handled by licensees
- •Global clinical trials and supply chains create cross-border exposure
Vir’s strategy is to advance differentiated immunology platforms into late-stage development, with emphasis on chronic...
01
Advance lead clinical programsshort-term
Late-stage progress is needed to create approvable assets and future commercial value.
02
Use strategic collaborationsmedium-term
Partnering reduces funding needs and adds commercial or development expertise.
03
Strengthen platform-based pipelinemedium-term
Multiple modalities can diversify scientific risk and broaden addressable markets.
Vir faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory delay, and dependence on...
Capital dependence
The company has not yet established a meaningful commercial base and may need additional financing.
- Scope
- Research, clinical trials, and commercialization build-out
- Materiality
- high
Partner concentration and contract risk
Revenue and development economics depend on collaboration terms and partner decisions.
- Scope
- GSK, Norgine, Alnylam, Astellas, Gates Foundation
- Materiality
- high
Manufacturing and CDMO execution
Biologics and siRNA programs rely on third-party suppliers and contract manufacturers.
- Scope
- Process development, cGMP supply, and clinical material production
- Materiality
- medium
Competitive pressure
Other biotech and pharma companies may reach the market first or with better therapies.
- Scope
- Infectious disease and oncology pipelines
- Materiality
- medium
Collaboration revenue and variable consideration
Can cause revenue volatility and retrospective adjustments
Grant and contract revenue recognition
Affects timing of reported revenue
Research and development expense recognition
Directly affects operating loss and comparability across periods
Fair value of contingent consideration
Can create non-cash gains or losses
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Vor Biopharma Inc.
VOR · Biological Products, (No Diagnostic Substances)
BiomX Inc.
PHGE · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
DYADIC INTERNATIONAL INC
DYAI · Biological Products, (No Diagnostic Substances)
Dyadic International is a U.S.-based biotechnology platform company that develops microbial protein production systems for industrial, life sciences, food and…
AIM ImmunoTech Inc.
AIM · Biological Products, (No Diagnostic Substances)
: 29.4.2026